Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab

BACKGROUND: The role of continuing anti-HER2 therapy beyond progression on front-line therapy in patients with metastatic HER2 positive gastro-oesophageal cancer (GEC) is unclear. Continued chemotherapy plus trastuzumab (CT) has never been compared with the current standard second-line treatment, ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Nevala-Plagemann, Christopher, Moser, Justin, Gilcrease, Glynn Weldon, Garrido-Laguna, Ignacio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677976/
https://www.ncbi.nlm.nih.gov/pubmed/31423338
http://dx.doi.org/10.1136/esmoopen-2019-000539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677976/
https://www.ncbi.nlm.nih.gov/pubmed/31423338
http://dx.doi.org/10.1136/esmoopen-2019-000539

Ejemplares similares